Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
40 Encephalopathy Trials near San Francisco, CA
Power is an online platform that helps thousands of Encephalopathy patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerImmune Suppression Therapy for Acute Liver Failure
San Francisco, CaliforniaThis trial tests two treatments that reduce immune activity in children with severe, unexplained liver failure. The treatments work by calming the immune system to prevent it from harming the liver.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:1 - 18
Sex:All
Key Eligibility Criteria
Disqualifiers:Hepatitis, HIV, Sepsis, Pregnancy, Others
Must Not Be Taking:Immunosuppressants, Chemotherapy
163 Participants Needed
LP352 for Epilepsy
San Francisco, CaliforniaThis (DEEp OLE Study) is a multicentre, open-label study to investigate the long-term safety, efficacy, tolerability, and pharmacokinetics (PK) of LP352 in the treatment of seizures in children and adults with DEE who completed Study LP352-301 or LP352-302. The study consists of 3 main phases: Screening, Titration period and Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 14 months.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:2 - 66
Sex:All
324 Participants Needed
LP352 for Epilepsy
San Francisco, CaliforniaThis (DEEp OCEAN Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DEE. The study consists of 3 main phases: Screening, Titration period, Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 24 months.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:2 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Dravet Syndrome, Neurodegenerative Disorders, Others
Must Be Taking:Antiseizure Medications
320 Participants Needed
Cooling Therapy for Pediatric Cardiac Arrest
San Francisco, CaliforniaThis trial is testing if cooling the body can help protect the brains of children who are in a coma after a heart attack. The researchers believe that keeping the body cool might help more children recover well or improve the recovery of those already doing well.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:2 - 17
Sex:All
Key Eligibility Criteria
Disqualifiers:Severe Neurodevelopmental Deficits, Terminal Illness, Trauma, Others
Must Not Be Taking:Epinephrine, Norepinephrine, Chemotherapy, Others
900 Participants Needed
Therapeutic Hypothermia for Cardiac Arrest
San Francisco, CaliforniaA multicenter, randomized, adaptive allocation clinical trial to determine if increasing durations of induced hypothermia are associated with an increasing rate of good neurological outcomes and to identify the optimal duration of induced hypothermia for neuroprotection in comatose survivors of cardiac arrest.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Neurological Disability, Terminal Illness, Sepsis, Others
1800 Participants Needed
Burst Suppression Therapy for Seizures after Cardiac Arrest
San Francisco, CaliforniaRESTORE is a randomized clinical trial investigating the safety and feasibility of using EEG treatment targets (burst suppression vs. seizure suppression) for post-cardiac arrest refractory status epilepticus treatment.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Acute Cerebral Hemorrhage, Pregnancy, Prisoners
30 Participants Needed
Fenfluramine for Dravet and Lennox-Gastaut Syndromes
San Francisco, CaliforniaThis is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome, Lennox-Gastaut syndrome or epileptic encephalopathy
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:2+
Sex:All
412 Participants Needed
NBI-921352 for Epilepsy
San Francisco, CaliforniaThe objective of this study is to assess the efficacy, safety, and pharmacokinetics of NBI-921352 as adjunctive therapy for seizures in subjects with SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE).
Stay on current meds
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:2 - 21
Sex:All
52 Participants Needed
NBI-921352 for Developmental and Epileptic Encephalopathy Syndrome
San Francisco, CaliforniaExtension study to evaluate how safe and tolerable the drug NBI-921352 is when used as adjunctive therapy in participants with SCN8A developmental and epileptic encephalopathy syndrome (SCN8A-DEE).
Stay on current meds
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Age:2 - 22
Sex:All
52 Participants Needed
STK-001 for Dravet Syndrome
San Francisco, CaliforniaThis trial is testing the safety of STK-001, a new treatment for Dravet syndrome. It aims to help patients by increasing a brain protein that is usually low in this condition. The study focuses on patients who have already tried this treatment in earlier studies.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Age:30+
Sex:All
60 Participants Needed
LP352 for Dravet Syndrome
San Francisco, CaliforniaThis (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance period, followed by a Taper period and Follow-Up. Participants will be randomized to LP352 or placebo. The total duration of the study will be approximately 24 months.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:2 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Infantile Spasms, Neurodegenerative Disorders, Others
Must Be Taking:Antiseizure Medications
160 Participants Needed
ETX101 for Dravet Syndrome
San Francisco, CaliforniaENDEAVOR is a Phase 1/2, 2-part, multicenter study to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged ≥6 to \<36 months (Part 1) and aged ≥6 to \<48 months (Part 2). Part 1 follows an open-label, dose-escalation design, and Part 2 is a randomized, double-blind, sham delayed-treatment control, dose-selection study.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:6 - 47
Sex:All
Key Eligibility Criteria
Disqualifiers:Genetic Mutation, CNS Abnormality, Others
Must Be Taking:Antiseizure Medications
22 Participants Needed
Therapeutic Hypothermia for Neonatal Encephalopathy
Oakland, CaliforniaThe TIME study is a randomized, controlled trial to evaluate impact on early measures of neurodevelopment and the safety profile of therapeutic hypothermia in term neonates with Mild Hypoxic-Ischemic Encephalopathy who are \< 6 hours of age. Neurodevelopmental outcome will be assessed at 12-14 months of age. The study will enroll 68 neonates randomized to therapeutic hypothermia or normothermia across 5 centers in California.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Age:< 6
Sex:All
68 Participants Needed
Rifaximin for Hepatic Encephalopathy
Redwood City, CaliforniaThis trial tests if rifaximin, an oral antibiotic, can delay brain problems in patients with liver cirrhosis and controlled fluid buildup by reducing harmful gut bacteria. Rifaximin has been shown to reduce the recurrence of brain-related issues and related hospitalizations.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18 - 85
Sex:All
466 Participants Needed
Donanemab for Early Alzheimer's Disease
Sherman Oaks, CaliforniaThis trial is testing different doses of donanemab, a drug aimed at helping people with early Alzheimer's disease. Donanemab has shown rapid reduction of brain amyloid in early Alzheimer's disease. The study will look at how often and how severely participants experience a side effect involving brain swelling. Researchers also want to find out which patient characteristics might predict this side effect.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:60 - 85
Sex:All
800 Participants Needed
Abemaciclib + Elacestrant for Brain Metastasis from Breast Cancer
Los Angeles, CaliforniaThis trial tests a combination of two drugs, elacestrant and abemaciclib, in patients with a specific type of breast cancer. It aims to find the best dose and see how well it works for those whose cancer has spread to the brain. The drugs work by blocking signals that help cancer cells grow and divide. Abemaciclib is a drug that has been approved for the treatment of certain advanced breast cancers.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Leptomeningeal Metastases, Concurrent Malignancy, Others
Must Not Be Taking:CYP3A4 Inducers/inhibitors, Herbal Meds
68 Participants Needed
Paracentesis vs. TIPS for Ascites
Los Angeles, CaliforniaFor this study, the investigators will be collecting data based on patients' random selection to two different approved standard of care treatments for ascites: Subjects will get randomized into either Group A: Large Volume Paracentesis (LVP) with albumin infusion, or Group B: an early transjugular intrahepatic portosystemic shunt (TIPS) procedure.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
68 Participants Needed
Multiple Therapies for Down Syndrome Regression Disorder
Los Angeles, CaliforniaThis trial is testing three treatments for Down Syndrome Regression Disorder (DSRD) in people with Down Syndrome. The treatments include a calming medication, an immune-boosting blood product, and a drug that reduces immune activity. The goal is to see which treatment is safest and most effective for managing severe symptoms.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:8 - 30
Sex:All
Key Eligibility Criteria
Disqualifiers:Genetic Disorder, Cardiac Disease, Viral Infection, Others
Must Not Be Taking:Immunosuppressants, Biologics, Chemotherapeutics, Others
66 Participants Needed
NBI-827104 for Epilepsy
Orange, CaliforniaThe primary objective for this study is to evaluate the long-term safety and tolerability of NBI-827104 in pediatric participants with epileptic encephalopathy with continuous spike-and-wave during sleep (EECSWS).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Age:4 - 12
Sex:All
24 Participants Needed
RLS-0071 for Hypoxic-Ischemic Encephalopathy
Orange, CaliforniaHypoxic-ischemic encephalopathy (HIE) affects approximately 4,000 to 12,000 persons annually in the United States. Mortality from HIE has been reported up to 60%, with at least 25% of survivors left with significant neurocognitive disability. Despite this vital unmet medical need, no pharmacological adjunct or alternative therapy has proven beneficial in improving outcomes in neonatal HIE.
RLS-0071 is a novel peptide being developed for the treatment of neonatal HIE. This study is designed to evaluate the safety and tolerability of RLS-0071 in the treatment of newborns with moderate or severe HIE.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:< 10
Sex:All
Key Eligibility Criteria
Disqualifiers:Congenital Abnormalities, Sepsis, Hypotension, Others
42 Participants Needed
Levetiracetam for Neonatal Seizures
San Diego, CaliforniaThis trial aims to find the safest and most effective dose of Levetiracetam (LEV) for treating seizures in newborns. LEV works by calming the brain's electrical activity to prevent or reduce seizures. Newborns with seizures will receive LEV, and if seizures continue, they will be given higher doses of LEV. Levetiracetam (LEV) has been studied extensively for its efficacy and safety in treating seizures across various age groups, including neonates, infants, children, and adults.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:< 1
Sex:All
Key Eligibility Criteria
Disqualifiers:Renal Failure, Imminent Death, Others
Must Be Taking:Levetiracetam
133 Participants Needed
Zagociguat for MELAS Syndrome
La Jolla, CaliforniaPRIZM is a Phase 2b randomized, double-blind, placebo-controlled, 3-treatment, 2-period, crossover study evaluating the efficacy and safety of oral zagociguat 15 and 30 mg vs. placebo when administered daily for 12 weeks in participants with genetically and phenotypically defined MELAS.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Low Blood Pressure, Orthostatic Hypotension, Active Cancer, Severe Gastrointestinal Dysmotility, Others
44 Participants Needed
Dexmedetomidine for Neonatal Encephalopathy
Salt Lake City, UtahManagement of neonatal pain and sedation often includes opioid therapy. A growing body of evidence suggests long-term harm associated with neonatal opioid exposure. Providing optimal sedation while neonates are undergoing therapeutic hypothermia (TH) may be beneficial but also presents therapeutic challenges. While there is evidence from animal models of brain injury and clinical trials in adults to support the safety and neuroprotective properties of dexmedetomidine (DMT), there are no published large clinical trials demonstrating safety and efficacy of DMT use in neonates with hypoxic-ischemic encephalopathy (HIE) during treatment with TH. This study is innovative in proposing a Phase II, 2-arm trial providing the opportunity to evaluate the use of DMT as compared to the use of morphine for sedation and pain management for babies undergoing TH. We propose to confirm optimal DMT dosing by collecting opportunistic pharmacokinetics (PK) data and determine safety of DMT in this population. These data will inform a larger phase III efficacy trial.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:< 24
Sex:All
Key Eligibility Criteria
Disqualifiers:Chromosomal Anomalies, Heart Defects, Others
50 Participants Needed
PRAX-562 for Epilepsy
Tacoma, WashingtonThis is a Phase 2, double-blind, randomized clinical trial to explore the safety, tolerability, efficacy, and pharmacokinetics of PRAX-562 in pediatric participants who have seizures associated with early-onset SCN2A-DEE and SCN8A-DEE.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:2 - 18
Sex:All
Key Eligibility Criteria
Disqualifiers:Other Genetic Variants, Status Epilepticus, Others
Must Not Be Taking:Sodium Channel Blockers
100 Participants Needed
Spinal Stimulation + Mobility Devices for Cerebral Palsy
Seattle, WashingtonThis research study will combine non-invasive spinal stimulation with mobility devices to examine the acute impact of the individual and combined effects of these innovative techniques on mobility in children with cerebral palsy.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:4 - 70
Sex:All
Key Eligibility Criteria
Disqualifiers:Hypertension, Seizures, Cancer, Others
Must Not Be Taking:Anticoagulants, Osteoporosis Medications
20 Participants Needed
Enhanced Physical Therapy for Stroke
Vancouver, British ColumbiaThe aim of this study is to assess the effect of implementing best practices into current stroke rehabilitation physical therapy on walking outcomes. Participants will also be provided an activity monitor to help them track and target their walking practice to determine if this can improve walking ability.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:19+
Sex:All
307 Participants Needed
Neuromonitoring for Hypoxic-Ischemic Brain Injury
Vancouver, British ColumbiaThis trial evaluates how well oxygen gets from the blood into the brain in patients who have had a cardiac arrest. It focuses on patients with brain injury due to lack of oxygen, checking both blood flow and oxygen movement into brain cells, as well as looking at markers for brain injury and inflammation.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:19+
Sex:All
Key Eligibility Criteria
Disqualifiers:Coagulopathy, Severe TBI, Stroke, Others
Must Not Be Taking:Anticoagulants, Antiplatelets
40 Participants Needed
XPro1595 for Alzheimer's Disease
West VancouverThe goal of this Phase 2 Alzheimer's study is to determine whether 1.0 mg/kg XPro1595 confers a benefit on cognition, function, and biomarkers of white matter and to further evaluate safety and tolerability. The objectives of this study are to determine the safety, tolerability, and efficacy of XPro1595 in patients with early ADi.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:50 - 85
Sex:All
201 Participants Needed
Phenylbutyrate for Neurodevelopmental Disorders
Aurora, ColoradoThis trial is testing glycerol phenylbutyrate, a medication that helps brain proteins work better, in children with severe genetic epilepsy and developmental delays. The goal is to see if it is safe and effective for these children.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Early Phase 1
Age:0 - 17
Sex:All
50 Participants Needed
Theophylline for Hypoxic-Ischemic Encephalopathy
Oklahoma City, OklahomaAcute kidney injury is a significant complication for infants who experience hypoxic ischemic encephalopathy, being associated with increased rates of death and prolonged hospitalization. This pilot study of theophylline administration soon after birth for the prevention of kidney injury will lay the foundation for the conduct of a larger clinical trial that seeks to identify a theophylline as a novel therapy to prevent kidney injury in thousands of at-risk infants.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:1 - 18
Sex:All
Key Eligibility Criteria
Disqualifiers:Renal Abnormalities, Brain Abnormalities, Heart Abnormalities, Lung Abnormalities, Others
30 Participants Needed
Page 1 of 2+
Learn More About Power
My name is Bask, and I helped to start the company here. We started Power when my Dad was diagnosed with multiple myeloma, and I needed a better way to understand how he could access the most promising immunotherapy for his illness.
Bask GillCEO at Power
Frequently Asked Questions
How much do Encephalopathy clinical trials in San Francisco, CA pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Encephalopathy clinical trials in San Francisco, CA work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Encephalopathy trials in San Francisco, CA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in San Francisco, CA for Encephalopathy is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in San Francisco, CA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Encephalopathy medical study in San Francisco, CA ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Encephalopathy clinical trials in San Francisco, CA ?
Most recently, we added Dexamethasone + Hyperbaric Oxygen for Carbon Monoxide Poisoning, Genome Sequencing for Hypoxic-Ischemic Encephalopathy and LP352 for Epilepsy to the Power online platform.